NovaBay Pharmaceuticals to Hold Second Quarter 2020 Conference Call on August 6
July 27 2020 - 6:50AM
Business Wire
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces it
will report financial results for the three and six months ended
June 30, 2020 after market close on Thursday, August 6, 2020 and
will hold an investment community conference call that day at 4:30
p.m. Eastern time.
“With completion of the warrant exercise last week we fully
expect to regain compliance with our NYSE listing, while raising
$6.8 million in gross proceeds to support our business strategy,”
said Justin Hall, NovaBay’s CEO. “As announced last week in an SEC
filing, we expect second quarter net sales to approximately double
from the first quarter, due primarily to sales of KN95 disposable
face masks, while operating loss is expected to decline 25% versus
the prior quarter. We look forward to providing a more detailed
review of our financial results and business progress during our
upcoming conference call.”
Conference Call and Webcast
DATE:
Thursday, August 6
TIME:
4:30 p.m. ET / 1:30 p.m. PT
DIAL IN:
800-608-8202 from within the U.S.
702-495-1913 from outside the U.S.
Enter conference identification number
7662239
The live call also will be available at
http://novabay.com/investors/events. A replay of the call will be
available beginning two hours after its completion through 11:59
p.m. Eastern time August 27, 2020 by dialing 855-859-2056 from
within the U.S. or 404-537-3406 from outside the U.S., and entering
conference ID 7662239. The call will also be archived at
http://novabay.com/investors/events.
About NovaBay Pharmaceuticals, Inc.: Going Beyond
Antibiotics®
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company
focusing on commercializing and developing its non-antibiotic
anti-infective products to address the unmet therapeutic needs of
the global, topical anti-infective market with its two distinct
product categories: the NEUTROX® family of products and the
AGANOCIDE® compounds. The Neutrox family of products includes
AVENOVA® for the eye care market, CELLERX® for the aesthetic
dermatology market and NEUTROPHASE® for the wound care market. The
Aganocide compounds, still under development, have target
applications in the dermatology and urology markets.
Forward-Looking Statements and Disclaimers
This release contains forward-looking statements that are based
upon management’s current expectations, assumptions, estimates,
projections and beliefs. These statements involve known and unknown
risks, uncertainties and other factors that may cause actual
results or achievements to be materially different and adverse from
those expressed in or implied by the forward-looking statements.
Factors that might cause or contribute to such differences include,
but are not limited to, risks and uncertainties relating to further
consumer acceptance of Avenova, and any potential damage to our
established goodwill in the marketplace. Other risks relating to
NovaBay’s business, including risks that could cause results to
differ materially from those projected in the forward-looking
statements in this press release, are detailed in NovaBay’s latest
Form 10-Q/K filings with the Securities and Exchange Commission,
especially under the heading “Risk Factors.” The forward-looking
statements in this release speak only as of this date, and NovaBay
disclaims any intent or obligation to revise or update publicly any
forward-looking statement except as required by law.
Socialize and Stay informed on
NovaBay’s progress: Like us on Facebook Follow
us on Twitter Connect with NovaBay on LinkedIn Visit
NovaBay’s Website
Avenova Purchasing
Information For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com.
www.Avenova.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200727005199/en/
NovaBay Contact Justin Hall,
Chief Executive Officer and General Counsel 510-899-8800
jhall@novabay.com
Investor Contact LHA
Investor Relations Jody Cain 310-691-7100 jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Apr 2023 to Apr 2024